Minerva Neurosciences
NERV
67 hedge funds and large institutions have $177M invested in Minerva Neurosciences in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 8 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 19
4% more capital invested
Capital invested by funds: $170M → $177M (+$6.5M)
0.03% more ownership
Funds ownership: 9.08% → 9.11% (+0.03%)
0% more funds holding
Funds holding: 67 → 67 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.19M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$1.28M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$552K |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$519K |
| 5 |
AG
Artal Group
Luxembourg
|
+$292K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ascend Capital
Orinda,
California
|
-$4.96M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$669K |
| 3 |
JP Morgan Chase
New York
|
-$348K |
| 4 |
BlackRock
New York
|
-$339K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$165K |
NERV Hedge Fund Activity: Q1 2018 in Review
67 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2018, worth a combined $177M — up 3.8% from $170M a quarter earlier.
Fund positioning in NERV was balanced in Q1 2018: 8 funds opened new positions, 8 closed out, 23 added to existing stakes and 19 trimmed.
The largest buyer was Millennium Management, adding an estimated $4.19M. The largest seller was Ascend Capital, exiting entirely with an estimated $4.96M sold.
- 67 institutional investors held Minerva Neurosciences (NERV) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $177M of Minerva Neurosciences stock for Q1 2018, up 3.8% quarter-over-quarter.
- 8 funds opened new Minerva Neurosciences positions in Q1 2018 and 8 closed out, a net change of 0 holders.
- The largest Minerva Neurosciences buyer in Q1 2018 was Millennium Management, an estimated $4.19M added.
- The largest Minerva Neurosciences seller in Q1 2018 was Ascend Capital, an estimated $4.96M sold.
Based on aggregated 13F filings for Q1 2018.